secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2021-12-23T23:59:59+00:00
Accession:  0001787306-21-000033
Event type: debt
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis secures $225M non-dilutive debt facility; FDA accepts NDA for roflumilast cream (PDUFA July 2022)
--------------------------------------------------------------------------------

- $75M drawn at closing; additional $125M available upon FDA approval of roflumilast cream for plaque psoriasis; $25M upon revenue milestones.
- Loan maturity January 2027; interest-only period for entire five years; floating rate = 7.45% + 1M SOFR.
- FDA accepted NDA for roflumilast cream (psoriasis) with PDUFA target action date of July 29, 2022.
- Proceeds extend cash runway into 2024; non-dilutive financing from SLR Capital Partners.
- Loan secured by substantially all assets; prepayment premiums of 3%/2%/1% declining over time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730621000033/0001787306-21-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730621000033/arqt-20211222.htm
  HTML page:      https://secwatch.observer/filing/0001787306-21-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer